Last reviewed · How we verify
Prednol
Prednol is a Small molecule drug developed by Dokuz Eylul University. It is currently in Phase 2 development. Also known as: Methylprednisolone.
Prednol is a type of steroid used in intralesional and intraoperative cavity administration for various conditions, including Idiopathic Granulomatous Mastitis and Nasal Polyposis. It is also used in combination with other treatments, such as autologous blood corticosteroid injections, for conditions like Lateral Epicondylitis.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Prednol |
|---|---|
| Also known as | Methylprednisolone |
| Sponsor | Dokuz Eylul University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Comparing Autologous Blood, Corticosteroid, and Their Combined Injection for Treating Lateral Epicondylitis (NA)
- Systemic Corticosteroids in Treatment of Post-COVID-19 Interstitial Lung Disease (PHASE4)
- Idiopathic Granulomatous Mastitis Combination Therapy (NA)
- Comparison of Methylprednisolone or Methotrexate in the Maintenance Treatment of Nasal Polyposis (PHASE2)
- Single Dose of Etomidate and Adrenal Cortex (PHASE4)
- Systemic Methylprednisolone in Chronic Rhinosinusitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prednol CI brief — competitive landscape report
- Prednol updates RSS · CI watch RSS
- Dokuz Eylul University portfolio CI
Frequently asked questions about Prednol
What is Prednol?
Who makes Prednol?
Is Prednol also known as anything else?
What development phase is Prednol in?
Related
- Manufacturer: Dokuz Eylul University — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Methylprednisolone
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing